Contraindicated combinations
With drugs that can prolong the OT interval and cause paroxysmal tachycardias, including a potentially lethal polymorphic ventricular tachycardia such as pirouette:
- with antiarrhythmic drugs IA class (quinidine, disopyramide) and III class (amiodarone, sotalol, dofetilide, ibutilide);
- with bepridilom, cisapride, methadone, sultopride, thioridazine, dipemannil methyl sulfate, erythromycin (intravenously), spiramycin (intravenously), misolastine, vincamine (intravenously), halofantrine, lumefantrine, sparfloxacin, gatifloxacin, moxifloxacin, pentamidine;
- with citalopram, escitalopram.
The risk of developing paroxysmal tachycardias increases, including potentially lethal ventricular tachycardia such as "pirouette" (see section "Contraindications").
With dopamine receptor agonists (cabergoline, quinagolide) when they are used not to treat Parkinson's disease.
Mutual antagonism of the effects of dopamine receptor agonists and neuroleptics. Dopamine receptor agonists can cause or exacerbate psychotic symptoms.
With levodopa (see the section "Contraindications")
Reciprocal antagonism of the effects of levodopa and neuroleptics.
Unrecommended combinations
With drugs that increase the risk of potentially lethal ventricular tachycardia such as "pirouette"
- with drugs that cause bradycardia (beta-blockers, verapamil, diltiazem, clopidine, guanfacine, cardiac glycosides, donepezil, rivastigmine, tacrine, ambenonium chloride, galactamine, pyridostigmine bromide, neostigmine bromide);
- with drugs that cause hypokalemia (with diuretics that cause hypokalemia, weak, simulating peristalsis of the intestine, intravenously administered amphotericin B, glucocorticosteroids, tetracosactides) - when using them, you must necessarily restore the loss of potassium and maintain a normal level of potassium in the blood;
- with some neuroleptics (haloperidol, pimozide, pipothiazine, sertindole, chlorpromazine, levomepromazine, cyamemazine, sulphopride,sultride, tiaprid, verialapride, droperidol), imipramine antidepressants, lithium preparations, azole antifungal agents.
The risk of developing ventricular arrhythmias increases, in particular, ventricular pirouette tachycardia.
- With ethanol
Amisulpride enhances the central effects of ethanol. Ethanol increases the sedative effect of neuroleptics.
- With dopamine receptor agonists (amantadine, apomorphine, bromocriptine, entacapone, lisuride, pergolide, piribedil, pramipexole, ropinirole, selegiline) (see the sections "Contraindications" and "Special instructions")
Mutual antagonism of the effects of dopamine receptor agonists and neuroleptics.
Dopamine receptor agonists can cause or exacerbate psychotic symptoms. Amisulpride can enhance the symptoms of Parkinson's disease.
Combinations that should be taken into account
With drugs that depress the central nervous system:
- Derivatives of morphine (analgesics, antitussives); barbiturates; benzodiazepines; non-benzodiazepine anxiolytics; hypnotics; antidepressants with sedative effect (amitriptyline, doxepin, mianserin, mirtazapine, trimipramine); H2 blockers of histamine receptors with sedative effect; antihypertensive drugs of central action (clonidine); Neuroleptics; baclofen; thalidomide, pisotifenom
Expressed increased oppressive effect on the central nervous system. An additional reduction in the concentration of attention, which creates a great danger for transport drivers and persons working with mechanisms.
- With antihypertensive drugs, including beta-blockers (bisoprolol, carvedilol, metoprolol)
The risk of developing arterial hypotension, in particular, orthostatic hypotension (additive effect). For beta-blockers, see also the section "Interaction with other drugs", subsection "Unrecommended combinations".